Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 13/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 13/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24161544 | 0.90 | DDB1 (0.52) | DDB1CRBNPOLBKCNA5ALDH1A1 | |
| SCHEMBL22128953 | 0.89 | DDB1 (0.55) | DDB1CRBNPOLBKCNA5ALDH1A1 | |
| SCHEMBL22117961 | 0.89 | DDB1 (0.55) | DDB1CRBNPOLBKCNA5ALDH1A1 | |
| SCHEMBL24161427 | 0.88 | DDB1 (0.51) | DDB1CRBNPOLBKCNA5ALDH1A1 | |
| SCHEMBL24161425 | 0.88 | DDB1 (0.51) | DDB1CRBNPOLBKCNA5ALDH1A1 | |
| SCHEMBL24161552 | 0.87 | DDB1 (0.67) | DDB1CRBNPOLBALDH1A1 | |
| SCHEMBL27178288 | 0.87 | DDB1 (0.47) | DDB1CRBNPOLBKCNA5ALDH1A1 | |
| SCHEMBL22118175 | 0.86 | DDB1 (0.55) | DDB1CRBNPOLBALDH1A1DRD4 | |
| SCHEMBL29403117 | 0.86 | DDB1 (0.55) | DDB1CRBNPOLBALDH1A1DRD4 | |
| Hydrochloric Acid SCHEMBL22117971 | 0.85 | DDB1 (0.54) | DDB1CRBNPOLBALDH1A1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2024-03-28 | — | — | US | disclosed |
| CN-116507333-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100170-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | DDB1 33/4885CRBN 91/4885POLB 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.